Based on the available knowledge and the research results obtained by us, it is possible to assume and try to extend the scope of research to search for new therapeutic drugs in cisplatin-resistant ovarian cancer, where the therapeutic target will be TIMP2. This evidence concerns the gene TIMP2 and ovarian cancer.